GEODE CAPITAL MANAGEMENT, LLC - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 182 filers reported holding HAEMONETICS CORP in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q2 2024$97,009,966
+1.0%
1,172,380
+4.2%
0.01%0.0%
Q1 2024$96,068,447
+3.5%
1,125,416
+3.7%
0.01%
-10.0%
Q4 2023$92,795,744
+0.2%
1,085,076
+5.0%
0.01%
-9.1%
Q3 2023$92,601,877
+9.7%
1,033,602
+4.3%
0.01%
+10.0%
Q2 2023$84,409,356
+8.1%
991,418
+5.1%
0.01%0.0%
Q1 2023$78,093,024
+108994.4%
943,722
+3.7%
0.01%0.0%
Q4 2022$71,583
-99.9%
910,152
+2.8%
0.01%0.0%
Q3 2022$65,555,000
+16.3%
885,524
+2.4%
0.01%
+25.0%
Q2 2022$56,366,000
+1.1%
864,784
-1.9%
0.01%
+14.3%
Q1 2022$55,732,000
+23.9%
881,561
+3.9%
0.01%
+40.0%
Q4 2021$44,996,000
-23.3%
848,356
+2.1%
0.01%
-37.5%
Q3 2021$58,657,000
+2.6%
830,959
-3.1%
0.01%0.0%
Q2 2021$57,149,000
-16.6%
857,591
+38.9%
0.01%
-20.0%
Q1 2021$68,539,000
-0.1%
617,413
+6.9%
0.01%
-16.7%
Q4 2020$68,584,000
+44.5%
577,553
+6.1%
0.01%
+33.3%
Q3 2020$47,476,000
-12.9%
544,140
-10.6%
0.01%
-25.0%
Q2 2020$54,485,000
-28.3%
608,378
-20.2%
0.01%
-40.0%
Q1 2020$75,978,000
-55.8%
762,378
-49.1%
0.02%
+11.1%
Q4 2019$171,950,000
+87.1%
1,496,540
+105.4%
0.02%
-14.3%
Q3 2019$91,925,000
+8.7%
728,761
+3.7%
0.02%
+5.0%
Q2 2019$84,539,000
+46.0%
702,502
+6.1%
0.02%
+33.3%
Q1 2019$57,895,000
-54.0%
661,822
-47.4%
0.02%
-21.1%
Q4 2018$125,800,000
+82.6%
1,257,390
+109.1%
0.02%0.0%
Q3 2018$68,902,000
+25.1%
601,351
-2.1%
0.02%
+11.8%
Q2 2018$55,059,000
+49.0%
613,957
+21.5%
0.02%
+41.7%
Q1 2018$36,963,000
+33.6%
505,239
+6.1%
0.01%
+33.3%
Q4 2017$27,657,000
+28.4%
476,203
-0.8%
0.01%
+12.5%
Q3 2017$21,547,000
+19.9%
480,218
+5.5%
0.01%
+14.3%
Q2 2017$17,971,000
-0.7%
455,090
+2.0%
0.01%0.0%
Q1 2017$18,096,000
+12.7%
446,049
+11.7%
0.01%0.0%
Q4 2016$16,051,000
+25.8%
399,302
+13.3%
0.01%
+16.7%
Q3 2016$12,763,000
+30.1%
352,486
+4.2%
0.01%
+20.0%
Q2 2016$9,809,000
-17.9%
338,371
-0.9%
0.01%
-16.7%
Q1 2016$11,946,000
+17.5%
341,519
+8.3%
0.01%0.0%
Q4 2015$10,165,000
+0.6%
315,310
+0.9%
0.01%0.0%
Q3 2015$10,101,000
-21.1%
312,532
+1.0%
0.01%
-14.3%
Q2 2015$12,797,000
-3.7%
309,407
+4.6%
0.01%
-12.5%
Q1 2015$13,286,000
+25.6%
295,782
+4.6%
0.01%
+33.3%
Q4 2014$10,579,000
+8.0%
282,713
+0.8%
0.01%0.0%
Q3 2014$9,797,000
-0.6%
280,584
+0.4%
0.01%0.0%
Q2 2014$9,860,000
+9.3%
279,502
+0.9%
0.01%0.0%
Q1 2014$9,025,000
-15.7%
276,945
+9.0%
0.01%
-14.3%
Q4 2013$10,703,000
+17.4%
254,060
+11.2%
0.01%0.0%
Q3 2013$9,113,000
+4.9%
228,513
+8.8%
0.01%
-12.5%
Q2 2013$8,688,000210,1190.01%
Other shareholders
HAEMONETICS CORP shareholders Q1 2017
NameSharesValueWeighting ↓
HealthCor Management, L.P. 538,962$61,927,0002.21%
Parkman Healthcare Partners LLC 60,250$6,923,0002.00%
Bridge City Capital, LLC 40,541$4,658,0001.92%
Millrace Asset Group, Inc. 14,665$1,685,0001.83%
Nitorum Capital, L.P. 280,586$32,239,0001.80%
COOKSON PEIRCE & CO INC 136,101$15,638,0001.38%
EMERALD ADVISERS, LLC 248,520$28,555,0001.21%
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 110,161$12,657,0001.20%
EMERALD MUTUAL FUND ADVISERS TRUST 239,240$27,489,0001.12%
Jackson Square Partners, LLC 1,778,966$204,403,0001.07%
View complete list of HAEMONETICS CORP shareholders